Search for: "ORTHO-MCNEIL PHARMACEUTICAL INC"
Results 121 - 140
of 184
Sorted by Relevance
|
Sort by Date
27 May 2010, 3:20 am
Anchen Pharmaceuticals Inc et al. [read post]
8 Sep 2011, 12:00 pm
Ortho-McNeil Pharmaceutical, Inc., 2011 WL 3566855 (N.D. [read post]
2 Jun 2011, 12:46 pm
Ortho Pharmaceutical Corp., 681 P.2d 1038, 1052 (Kan. 1984). [read post]
7 Nov 2014, 5:52 am
Teva Pharmaceuticals USA, Inc., 819 F. [read post]
13 Nov 2013, 1:13 pm
Ortho-McNeil Pharmaceutical, Inc., 2013 U.S. [read post]
23 Apr 2010, 8:20 am
” Expected to attend are IP leaders from BP America Inc., Merck & Co., Inc., Bose, Brigham Young University, Cornell University, Stanford University, Duke University, Georgetown University, GlaxoSmithKline, Honeywell, Harvard University, Johnson & Johnson, Kauffman Foundation, Lockheed Martin, Massachusetts Institute of Technology (MIT), Mayo Clinic, Ortho-McNeil Pharmaceuticals Inc., Rutgers, Syngenta Biotechnology, Scripps… [read post]
10 Jun 2009, 10:00 pm
Ortho-McNeil Pharmaceutical, 2007 WL 121149, at *4 (S.D. [read post]
28 Oct 2007, 6:02 am
Axcan Scandipharm Inc. v. [read post]
18 Jan 2016, 5:00 am
Ortho-McNeil-Janssen Pharmaceuticals, Inc., 808 F.3d 281 (6th Cir. 2015) – preemption, but not involving generic drugs − which aptly described pre-approval theories as “never-start selling” claims (id. at 300), describes that other decision. [read post]
25 Aug 2011, 8:14 am
Bayer Schering, 575 F.3d at 1347 (citing O’Farrell, 853 F.2d at 903); see also Ortho-McNeil, 520 F.3d at 1364 (stating the number of options must be “small or easily traversed”). [read post]
25 Aug 2011, 8:14 am
Ortho-McNeil, 520 F.3d at 1364-65 (“[A] flexible TSM test remains the primary guarantor against a non-statutory hindsight analysis . . . . [read post]
22 Apr 2016, 12:51 pm
Ortho-McNeil-Janssen Pharmaceuticals, Inc., 808 F. 3d 281 (6th Cir. 2015); In re Celexa & Lexapro Marketing & Sales Practices Litigation, 779 F.3d 34 (1st Cir. 2015).Now there are three, and the latest is the most a fortiori of the lot.The Third Circuit has applied the Mensing/Bartlettimpossibility preemption rationale outside of the FDCA altogether, to preemption of design defect claims involving airplanes. [read post]
1 Jul 2009, 1:06 am
Levaquin, made by J&J subsidiary Ortho-McNeil Pharmaceutical Inc., was approved by the Food and Drug Administration in 1996, but in July 2008, the FDA warned that Levaquin, and other drugs in the fluoroquinolone class of antibiotics, put users at heightened risk of developing tendonitis and tendon ruptures. [read post]
7 Feb 2011, 6:53 pm
In Ortho-McNeil Pharmaceutical, Inc. v. [read post]
24 Sep 2010, 1:15 pm
Ortho-McNeil Pharmaceutical, Inc. v. [read post]
10 Mar 2014, 11:31 am
Ortho-McNeil-Janssen Pharmaceuticals, 2013 WL 2917651, at *28 (Pa. [read post]
3 Mar 2016, 5:19 am
Biomet, Inc., 492 F. [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
2 Sep 2010, 10:51 am
Ortho-McNeil Pharmaceutical, Inc. v. [read post]
